<DOC>
	<DOCNO>NCT00809965</DOCNO>
	<brief_summary>The purpose study determine whether rivaroxaban addition standard care reduces risk composite cardiovascular death , myocardial infarction , stroke patient recent acute coronary syndrome compare placebo .</brief_summary>
	<brief_title>An Efficacy Safety Study Rivaroxaban Patients With Acute Coronary Syndrome</brief_title>
	<detailed_description>Acute coronary syndrome ( ACS ) serious life threaten condition . Following acute coronary syndrome event patient risk important additional clinical event death , myocardial infarction , stroke . Six month patient present index event ST-segment myocardial infarction , approximately 15 % either die another episode myocardial ischemia , similar situation exist non-ST-segment elevation myocardial infarction/unstable angina patient . This randomize ; double-blind ; placebo control study evaluate efficacy safety rivaroxaban addition standard care patient recent ACS . Patients give rivaroxaban ( 2.5 mg twice daily 5 mg twice daily ) placebo ( twice daily ) addition standard care .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Patients must currently receive aspirin therapy alone combination thienopyridine per national local dose recommendation Have hospitalize symptom suggestive acute coronary syndrome last least 10 minute rest occur 48 hour less go hospital Any condition , opinion investigator , contraindicate anticoagulant therapy would unacceptable risk bleed Need continue anticoagulant therapy Significant renal impairment know significant liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Rivaroxaban</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>ACS</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Thienopyridine</keyword>
	<keyword>Unstable Angina</keyword>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Anticoagulation</keyword>
	<keyword>Clopidogrel ( Plavix )</keyword>
</DOC>